Abstract
In the past decade there have been substantial improvements in the treatment of patients with muscle-invasive bladder cancer. Patients now experience less short- and long-term morbidity from radical surgery, radical radiotherapy, or a combination of the two techniques [1]. In addition to these technical advances, new investigative tools are now available such as DNA flow cytometry and cell surface markers. In the near future evaluation of somatic point mutations in important tumor suppressor genes in the tumors of individual patients will be possible. However, while these latter factors may well lead to an improved understanding of the histogenesis and heterogeneity of invasive bladder tumors, they have not as yet been shown to be useful in predicting the success or failure of any of the commonly utilized treatment modalities [2].
This article is also being published simultaneously in Meyer JL (ed) (1991) Radiotherapy, chemotherapy interaction in cancer treatment. Frontiers of Radiation Therapy and Oncology, Vol. 26. Karger, Basel.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Richie JP, Shipley WU, Yagoda A (1989) Cancer of the bladder. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 3rd edn. Lippincott, Philadelphia, pp 1008–1022
Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP (1990) Biology and management of bladder cancer. N Engl J Med 322:1129–1138
Prout GR Jr, Griffin PP, Shipley WU (1979) Bladder cancer as a systemic disease. Cancer 43:2532–2539
Shipley WU, Rose MA, Perrone TL, Mannix CM, Heney NM, Prout GR Jr (1985) Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histologic factors prognostic of improved survival. J Urol 134:679–683
Sternberg CN, Yagoda A, Scher HI et al. (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139:461–469
Miller LS, Bladder Cancer (1977) Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 39:973–980
Bloom HJG, Hendry WF, Wallace DM, Skeet RG (1982) Treatment of T3 bladder cancer: Controlled trial of preoperative radiotherapy and radical cystectomy versus radical radiotherapy: second report and review. Br J Urol 54:136–151
Barlebo B, Steven K, Sorensen BL et al. (1990) Preoperative radiation (40 Gy) and cystectomy vs. radiotherapy (60 Gy) followed by salvage cystectomy in the treatment of advanced bladder cancer (T2-T4A). A randomized study (DAZECA-8201). J Urol 143:291 A
Barnes RW, Dick AL, Hadley HL et al. (1977) Survival following transurethral resection of bladder carcinoma. Cancer Res 37:2895–2899
Herr HW (1987) Conservative management of muscle-infiltrating bladder cancer: Prospective experience. J Urol 138:1161–1163
Hall RR (1986) Transurethral resection and systemic chemotherapy as primary treatment for T3 bladder cancer. In: Yagoda A (ed) Bladder cancer: future directions for treatment. Park Row, New York, pp 117–122
Shipley WU, Kaufman DS, Heney NM (1990) Can chemo-radiotherapy plus transurethral tumor resection make cystectomy unnecessary for invasive bladder cancer? Oncology 4:25–32
Scher H, Herr H, Sternberg C et al. (1989) Neo-adjuvant chemotherapy for invasive bladder cancer: Experience with the M-VAC regimen. Br J Urol 64:250–256
Shipley WU, Prout GR Jr, Einstein AB Jr, Coombs LJ, Wajsman Z, Soloway MS, Englander LS, Barton BA, Hafermann MD (1987) Treatment of invasive bladder cancer by cisplatin and irradiation in patients unsuited for surgery: a high success rate in clinical stage T2 tumors in a National Bladder Cancer Group Trial. JAMA 258:931–935
Jaske G, Frommhold H, Nedden DZ (1985) Combined radiation and chemotherapy for locally advanced transitional cell carcinoma of the urinary bladder. Cancer 55:1659–1664
Rotman M, Macchia R, Silverstein R et al. (1987) Treatment of advanced bladder carcinoma with irradiation and concomitant 5-Fluorouracil infusion. Cancer 59:710–714
Sauer R, Dunst J, Altendorf-Hofman A et al. (1990) Radiotherapy with or without Cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 19:687–691
Eapen L, Stuart D, Danjoux C et al. (1989) Intra-arterial cisplatin and concurrent radiation for locally advanced bladder cancer. J Clin Oncol 7:230–235
Wajsman Z, Klimberg I, Parsons J et al. (1989) Bladder sparing treatment for muscle invasive transitional cell carcinoma: Systemic chemotherapy followed by radiation therapy with adjunctive cisplatin. Proc Am Soc Clin Oncol 8:132
Prout GR Jr, Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, Bassil B, Nocks BN, Parkhurst EC, Young HH III (1990) Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J Urol 144:1128–1136
Heaney JA, Tester WJ, Porter AT et al. (1990) Combined modality program with possible organ preservation for invasive bladder carcinoma; preliminary results of RTOG protocol 85-12. J Urol 143:290A
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Shipley, W.U., Kaufman, D.S., Griffin, P.P., Althausen, A.F., Heney, N.M., Prout, G.R. (1993). Radiochemotherapy for Invasive Carcinoma of the Bladder. In: Ackermann, R., Diehl, V. (eds) Malignancies of the Genitourinary Tract. Recent Results in Cancer Research, vol 126. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84583-3_19
Download citation
DOI: https://doi.org/10.1007/978-3-642-84583-3_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-84585-7
Online ISBN: 978-3-642-84583-3
eBook Packages: Springer Book Archive